Question Everything. See who's reporting it.

Personalised cancer vaccine cuts skin cancer recurrence risk by 42%: What this means for patients

Source: Indian Express

The story in brief

A personalized cancer vaccine, intismeran, reduced skin cancer recurrence risk by 42% in a trial, with 82.2% of patients remaining recurrence-free after two years. The treatment targets high-risk melanoma patients post-surgery and faces regulatory review. Common side effects include fever and fatigue, while affordability and infrastructure remain key challenges.

3 outletsSee what the other 2 outlets said

NEWXFree on Android and iPhone. Open in NEWX